OXOAZEPANYLACETAMIDE AND OXOAZEPANYLPHENOXYACETAMIDE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND METHOD FOR INHIBITING HEPATITIS TYPE C VIRUS (HCV) REPLICATION Russian patent published in 2011 - IPC C07D223/12 C07D211/74 C07D281/10 C07D401/12 A61K31/55 A61P1/16 

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to new oxoazepanylacetamide and oxoazepanylphenoxyacetamide derivatives, or to their stereoisomers or pharmaceutically acceptable salts described by general formula I where Q means O, S or N(R₂₅); R₂₅ means H; R₈₀ is C₆arylC_1-4alkyl substituted by one or two substituted independently chosen from R₃ groups; each R₃ is independently chosen from a group including C_1-4alkyl, C_1-4alkoxy group, C_2-6alkenyloxy group, halogen, C₆aryloxy group, N(R₂₀)(R₂₁), R₅₀, heteroaryl chosen from pyridine and thiazol where each alkoxy group and heteroaryl has optionally up to three substitutes independently chosen from R₆₁ groups; and alkyl has optionally three substitutes independently chosen from R₆₀ groups; or two R₃ groups when they are present on carbon neighbours, together can form a fragment of formula -(O)_a-(CH₂)_b-(O)_c-(CH₂)_d-(O)_e- where a, c and e independently mean 0 or 1, and both b and d independently mean 0, 1, 2 or 3; provided the fragment does not contain two oxygen neighbors and summed a, b, c, d and e are equal to 3 at least; R₁ is chosen from a group including H, C_1-4alkyl, C₆arylC_1-4alkyl; each R₆₀ independently is chosen from a group including C₁-C₆a alkoxy group, NR₁₂R₁₃, halogen, heterocycloalkyl, such as piperidine; each R₆₁ independently is chosen from a group including R₆₀ and C₁-C₆alkyl; X means a group of formula -(CH₂)_n- where n means 2 or 3; or a group of formula II where Y means CH₂, S; R₇₅ and R₇₆ means H; Z means C₆aryl or heteroaryl, such as pyridine; each of which has optionally one substitutes chosen from R₂ groups; R₂ is chosen from a group including H, C_1-4alkyl, halogen, heterocycloalkylC_1-4alkyl, C₆arylC_1-4alkylaminoC_1-4alkyl and a group of formula -(CH₂)_fN(R₁₁)-(R₁₀); where each heterocycloalkyl, arylalkylaminoalkyl has oprtionally one substitute chosen from R₆₁ groups; f means 1; R₁₁ means H; R₁₀ means C_1-6alkyl, C_2-6alkenyl, C_3-8cycloalkyl, aryl, C₆arylC_1-4alkyl, heteroarylC_1-4alkyl where aryl has optionally one substitute chosen from R₆₁ groups; each R₁₂ and R₁₃ independently mean C_1-4alkyl; each R₂₀ and R₂₁ independently mean C_1-4alkyl where alkyl has optionally one substitute chosen from R₆₀ groups; and provided that the compound does not represent N-(4-ethoxybenzyl)-N-(2-oxoazepane-2-yl)-2-phenoxyacetamide or N-[(2-fluorophenyl)methyl]-N-(2- oxoazepane-3-yl)-2,2-diphenylacetamide. Also, the invention refers to a pharmaceutical composition of the compound of formula I, to methods of treating HCV viral infection and methods of relieving the symptoms of HCV viral infection with using the compound of formula I.

EFFECT: there are produced new oxoazepanylacetamide and oxoazepanylphenoxyacetamide derivatives showing HCV replication inhibiting activity.

1 tbl, 9 ex